<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.5.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art550.dtd?><?SourceDTD.Version 5.5.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_CJTEE289 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin J Traumatol</journal-id><journal-id journal-id-type="iso-abbrev">Chin. J. Traumatol</journal-id><journal-title-group><journal-title>Chinese Journal of Traumatology</journal-title></journal-title-group><issn pub-type="ppub">1008-1275</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6114124</article-id><article-id pub-id-type="publisher-id">S1008-1275(16)30274-7</article-id><article-id pub-id-type="doi">10.1016/j.cjtee.2017.04.012</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Normal saline for intravenous fluid therapy in critically ill patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Fei-Hu</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chao</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Zhi</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Peng-Lin</given-names></name><email>mapenglin1@163.com</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Critical Care Medicine, Chinese People's Liberation Army General Hospital, Beijing 100853, China</aff><aff id="aff2"><label>b</label>Department of Critical Care Medicine, 309th Hospital of Chinese People's Liberation Army, Beijing 100091, China</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. <email>mapenglin1@163.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>31</day><month>1</month><year>2018</year></pub-date><volume>21</volume><issue>1</issue><fpage>11</fpage><lpage>15</lpage><history><date date-type="received"><day>10</day><month>9</month><year>2016</year></date><date date-type="rev-recd"><day>5</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>13</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Production and hosting by Elsevier B.V. on behalf of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder/><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>The efficacy and safety of normal saline (NS) for fluid therapy in critically ill patients remain controversy. In this review, we summarized the evidence of randomized controlled trials (RCTs) which compared NS with other solutions in critically ill patients. The results showed that when compared with 6% hydroxyethyl starch (HES), NS may reduce the onset of acute kidney injury (AKI). However, there is no significant different in mortality and incidence of AKI when compared with 10% HES, albumin and buffered crystalloid solution. Therefore, it is important to prescribe intravenous fluid for patients according to their individual condition.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Normal saline</kwd><kwd>Critical care</kwd><kwd>Fluid resuscitation</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Fluid resuscitation is a fundamental component of the management of acutely ill patients. The optimal dose and types of intravenous (IV) fluid for resuscitation remain undetermined.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref> 0.9% sodium chloride, or the so-called &#x0201c;normal saline&#x0201d; (NS), is one of the most commonly used IV fluid for seriously ill or injured patients. Since NS has a totally different level of chloridion from the plasma, its administration would be inevitably causes hyperchloremic metabolic acidosis.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref> And the chloride has an important role in tubuloglomerular feedback mechanisms.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> As the chloride concentration in the distal tubule fluid rises, feedback occurs via the macula densa, the afferent arteriole constricts, and the glomerular filtration rate drops.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> However, whether this adverse event will affect mortality and the incidence of acute kidney injury (AKI) remains unknown. Meanwhile, whether the NS is the solution for crystalloid resuscitation<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> or not the first choice for crystalloid resuscitation<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> remains controversy.</p><p id="p0015">Therefore, we summarized the evidence of randomized controlled trials (RCTs) which compared NS with other solutions in critically ill patients. The results were expected to lead to a better use of NS in critically ill patients, and may influence clinical outcomes positively.</p></sec><sec id="sec2"><title>NS for fluid resuscitation in critically ill patients</title><p id="p0020">We selected RCTs comparing NS with other solutions in adult critically ill patients who required IV fluid therapy. The search strategy and inclusion criteria are listed in <xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>. The statistical analysis was performed using RevMan software (version 5.2; Cochrane Collaboration, Copenhagen, Denmark) for outcome measurements. The results of the risk ratio (<italic>RR</italic>) for dichotomous outcomes or the mean difference (MD) for continuous data were expressed as means and 95% confidence intervals (<italic>CI</italic>). A random-effects model was used regardless of heterogeneity. A <italic>p</italic> value less than 0.05 was considered to indicate a statistically significant difference. The outcomes reported across studies included mortality at 28 and 90 days, renal outcomes, and length of stay in intensive care units (ICU).<table-wrap id="tbl1" position="float"><label>Table&#x000a0;1</label><caption><p>Search strategy and inclusion criteria.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td colspan="2">Review eligibility structure</td></tr><tr><td>&#x000a0;Population</td><td>Critically ill patients requiring acute volume replacement (e.g. resuscitation, but not maintenance fluid)</td></tr><tr><td>&#x000a0;Intervention</td><td>Normal saline</td></tr><tr><td>&#x000a0;Control</td><td>HES solutions, albumin, dextran, gelatin or buffered crystalloid solution</td></tr><tr><td>&#x000a0;Outcomes</td><td>Primary outcome: incidence of mortality.<break/>Secondary outcomes: renal function, use of renal replacement therapy, lengths of stay in ICU, incidence of patients requiring of red cell transfusion.</td></tr><tr><td>&#x000a0;Study design</td><td>Prospective randomized controlled trials</td></tr><tr><td colspan="2">Review eligibility criteria</td></tr><tr><td rowspan="4">&#x000a0;Inclusion criteria</td><td>1. Randomized controlled trial;</td></tr><tr><td>2. Participants' age &#x02265;18 years;</td></tr><tr><td>3. Indication for acute volume resuscitation (e.g. hypovolemia, hypotension, inadequate indicators of pre-load or filling pressures);</td></tr><tr><td>4. Allocation to resuscitation with normal saline compared with HES, albumin, or buffered crystalloid solution.</td></tr><tr><td rowspan="5">&#x000a0;Exclusion criteria</td><td>1. Fluids used as maintenance rather than resuscitation;</td></tr><tr><td>2. What control group used is whole blood, or blood products;</td></tr><tr><td>3. Use of normal saline for elective pre-operative volume loading;</td></tr><tr><td>4. Elective surgical procedures (e.g. cardiac surgery);</td></tr><tr><td>5. Observational study designs, quasi-randomized, cross-over, or cluster randomized trials.</td></tr></tbody></table></table-wrap></p></sec><sec id="sec3"><title>NS vs 6% hydroxyethyl starch (HES)</title><p id="p0025">Seven RCTs investigated the efficacy and safety of 6% HES vs NS during the IV fluid therapy in critically ill patients. The results (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>) showed that more patients in the 6% HES group met the RIFLE (risk, injury, failure, loss, end-stage kidney disease) criteria for risk and injury (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Therefore, compared to NS, 6% HES may increase the risk of AKI when prescribed for critically ill patients. However, no significant differences were found between 6% HES and NS in all-cause mortality (at 28 days or at 90 days), renal replacement therapy, RBC transfusion and length of stay in ICU when used for fluid resuscitation in critically ill patients. No RCTs analysed the cost-effectiveness of the two fluid therapies. One cohort study did a pre-specified cost-effectiveness analysis from New South Wales enrolled in the Crystalloid vs HES trial (CHEST, <ext-link ext-link-type="uri" xlink:href="ctgov:NCT00935168" id="intref0010">NCT00935168</ext-link>),<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> and found that the total hospital costs (including ICU costs) at 24 months were similar between the HES and saline groups ($62,196 vs $62,617; <italic>p</italic>&#x000a0;=&#x000a0;0.83). This suggested that there may be no difference in hospital costs when these two fluids were prescribed for fluid resuscitation in critically ill patients.<table-wrap id="tbl2" position="float"><label>Table&#x000a0;2</label><caption><p>Comparison of 6% HES and NS on fluid resuscitation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameters</th><th colspan="2">No. of patients<hr/></th><th rowspan="2"><italic>RR</italic> (95% <italic>CI</italic>)</th><th rowspan="2">Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</th><th rowspan="2">Test for effect (<italic>p</italic> value)</th></tr><tr><th>HES</th><th>NS</th></tr></thead><tbody><tr><td>All-cause mortality (90 days)<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref></td><td>828/4089</td><td>958/4497</td><td>0.97 (0.81, 1.16)</td><td>51% (0.07)</td><td>0.73</td></tr><tr><td>All-cause mortality (28 days)<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref></td><td>647/4073</td><td>746/4476</td><td>0.99 (0.86, 1.13)</td><td>27% (0.25)</td><td>0.85</td></tr><tr><td>All-cause mortality 28 days)&#x02013;trauma<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></td><td>12/56</td><td>6/53</td><td>1.89 (0.77&#x02013;4.68)</td><td>Not applicable</td><td>0.17</td></tr><tr><td>All-cause mortality (28 days)&#x02013;sepsis<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib15" ref-type="bibr">15</xref></td><td>136/475</td><td>181/652</td><td>1.03 (0.85, 1.25)</td><td>0% (0.41)</td><td>0.75</td></tr><tr><td>AKI- RIFLE- risk<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib17" ref-type="bibr">17</xref></td><td>1809/3465</td><td>1935/3483</td><td>0.94 (0.90, 0.98)</td><td>0% (0.56)</td><td>0.006</td></tr><tr><td>AKI-RIFLE- risk&#x02013;trauma<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></td><td>8/56</td><td>12/53</td><td>0.63 (0.28, 1.42)</td><td>Not applicable</td><td>0.27</td></tr><tr><td>AKI-RIFLE- risk&#x02013;sepsis<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></td><td>13/100</td><td>11/95</td><td>1.12 (0.53, 2.38)</td><td>Not applicable</td><td>0.76</td></tr><tr><td>AKI-RIFLE- injury<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib17" ref-type="bibr">17</xref></td><td>1138/3421</td><td>1266/3488</td><td>0.91 (0.85, 0.97)</td><td>0% (0.51)</td><td>0.004</td></tr><tr><td>AKI-RIFLE-injury&#x02013;trauma<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></td><td>4/56</td><td>8/53</td><td>0.47 (0.15, 1.48)</td><td>Not applicable</td><td>0.20</td></tr><tr><td>AKI-RIFLE-injury&#x02013;sepsis<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></td><td>4/100</td><td>5/95</td><td>0.76 (0.21, 2.75)</td><td>Not applicable</td><td>0.68</td></tr><tr><td>AKI- RIFLE- failure<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref></td><td>341/3343</td><td>308/3470</td><td>1.15 (0.99, 1.33)</td><td>0% (0.35)</td><td>0.06</td></tr><tr><td>AKI-RIFLE- failure&#x02013;sepsis<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></td><td>5/100</td><td>7/95</td><td>0.68 (0.22, 2.06)</td><td>Not applicable</td><td>0.49</td></tr><tr><td>Renal replacement therapy<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib17" ref-type="bibr">17</xref></td><td>237/3408</td><td>199/3428</td><td>1.20 (1.00, 1.44)</td><td>0% (0.47)</td><td>0.05</td></tr><tr><td>Use of renal replacement therapy&#x02013;trauma<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref></td><td>2/56</td><td>3/53</td><td>0.63 (0.11, 3.63)</td><td>Not applicable</td><td>0.61</td></tr><tr><td>RBC transfusion<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><hr/></td><td>29/100<hr/></td><td>20/96<hr/></td><td>1.38 (0.84, 2.26)<hr/></td><td>Not applicable<hr/></td><td>0.21<hr/></td></tr><tr><td/><td colspan="2">Length of stay<hr/></td><td>MD (95% <italic>CI</italic>)</td><td>Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</td><td>Test for effect (<italic>p</italic> value)</td></tr><tr><td><hr/></td><td>HES<hr/></td><td>NS<hr/></td><td><hr/></td><td><hr/></td><td><hr/></td></tr><tr><td>Guidet et&#x000a0;al<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref></td><td>15.4&#x000a0;&#x000b1;&#x000a0;11.1</td><td>20.2&#x000a0;&#x000b1;&#x000a0;22.2</td><td rowspan="2">&#x02212;1.58 (&#x02212;6.53, 3.37)</td><td rowspan="2">76% (0.04)</td><td rowspan="2">0.53</td></tr><tr><td>Myburgh et&#x000a0;al<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref></td><td>7.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td>6.9&#x000a0;&#x000b1;&#x000a0;0.2</td></tr></tbody></table><table-wrap-foot><fn><p>AKI: acute kidney injury; <italic>CI</italic>: confidence interval; HES: hydroxyethyl starch; MD: mean difference; NS: normal saline; RIFLE: risk, injury, failure, loss, end-stage kidney disease; <italic>RR</italic>: relative risk.</p></fn></table-wrap-foot></table-wrap></p><p id="p0030">From the acquired evidence, when 6% HES was prescribed for critically ill patients, we must take more attention on the change of renal function and give supportive treatment immediately. More studies are needed and should focus on long-term outcomes, clinical relative adverse events and the impact on coagulation.</p></sec><sec id="sec4"><title>NS vs 10% HES</title><p id="p0035">Only two RCTs<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> with 86 patients were enrolled in the comparison of NS vs 10% HES (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). The results show that there were no differences in all-cause mortality (at 28 days), renal failure and length of stay in ICU between the two groups. For the limited patient data, the conclusion has high risk of inconsistency and thus cannot be applied to guide the clinical practice. It is necessary to use 10% HES according to patients' individual status.<table-wrap id="tbl3" position="float"><label>Table&#x000a0;3</label><caption><p>Comparison of 10% hydroxyethyl starch (HES) and NS on fluid resuscitation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Parameters</th><th colspan="2">No. of patients<hr/></th><th rowspan="2"><italic>RR</italic> (95% <italic>CI</italic>)</th><th rowspan="2">Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</th><th rowspan="2">Test for effect (<italic>p</italic> value)</th></tr><tr><th>HES</th><th>NS</th></tr></thead><tbody><tr><td>All-cause mortality (28 days)<xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref></td><td>27/51</td><td>11/35</td><td>1.63 (0.92, 2.88)</td><td>Not applicable</td><td>0.47</td></tr><tr><td>All-cause mortality (28 days)&#x02013;sepsis<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></td><td>9/21</td><td>6/19</td><td>1.36 (0.59, 3.10)</td><td>0% (0.41)</td><td>0.75</td></tr><tr><td>AKI- RIFLE- failure &#x02013;sepsis<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><hr/></td><td>3/21<hr/></td><td>1/19<hr/></td><td>2.71 (0.31, 23.93)<hr/></td><td>Not applicable<hr/></td><td>0.37<hr/></td></tr><tr><td/><td colspan="2">Length of stay<hr/></td><td>MD (95% <italic>CI</italic>)</td><td>Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</td><td>Test for effect (<italic>p</italic> value)</td></tr><tr><td><hr/></td><td>HES<hr/></td><td>NS<hr/></td><td><hr/></td><td><hr/></td><td><hr/></td></tr><tr><td>McIntyre et&#x000a0;al<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></td><td>7.5 (3&#x02013;13)</td><td>5 (1&#x02013;13)</td><td>1.50 (&#x02212;4.01, 7.01)</td><td>Not applicable</td><td>0.59</td></tr></tbody></table><table-wrap-foot><fn><p>AKI: acute kidney injury; <italic>CI</italic>: confidence interval; HES: hydroxyethyl starch; MD: mean difference; NS: normal saline; RIFLE: risk, injury, failure, loss, end-stage kidney disease; <italic>RR</italic>: relative risk.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec5"><title>NS vs. albumin</title><p id="p0040">Five RCTs<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib20" ref-type="bibr">20</xref> evaluated the efficacy and safety of albumin vs NS during the IV fluid therapy in critically ill patients (<xref rid="tbl4" ref-type="table">Table&#x000a0;4</xref>). There were no differences in all-cause mortality (at 28 days or at 90 days), renal function, renal replacement therapy and length of stay in ICU between albumin and NS groups. Furthermore, two recent meta-analysis<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> evaluated albumin vs other fluids for resuscitation in patients with sepsis and suggested that the present evidence did not demonstrate significant advantage of using human albumin&#x000a0;solutions at reducing all-cause mortality. Meanwhile, Jiang et&#x000a0;al<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> reported that 4%&#x02013;5% albumin may be relative safer than 20%&#x02013;25% albumin for fluid resuscitation. However, the high cost of albumin may limit its wide applicability.<xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref> Therefore, according to the current state of knowledge, we should carefully consider the hospital costs and the concentration when albumin was prescribed for critically ill patients.<table-wrap id="tbl4" position="float"><label>Table&#x000a0;4</label><caption><p>Comparison of albumin and NS on fluid resuscitation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">No. of patients<hr/></th><th rowspan="2"><italic>RR</italic> (95% <italic>CI</italic>)</th><th rowspan="2">Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</th><th rowspan="2">Test for effect (<italic>p</italic> value)</th></tr><tr><th>albumin</th><th>NS</th></tr></thead><tbody><tr><td>All-cause mortality (90 days)<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib15" ref-type="bibr">15</xref></td><td>36/101</td><td>355/3055</td><td>1.39 (0.48, 4.01)</td><td>87% (0.0006)</td><td>0.54</td></tr><tr><td>All-cause mortality (28 days)<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib20" ref-type="bibr">20</xref></td><td>759/3568</td><td>1009/4511</td><td>1.06 (0.87, 1.29)</td><td>29% (0.25)</td><td>0.58</td></tr><tr><td>All-cause mortality 28 days)&#x02013;trauma<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref></td><td>81/596</td><td>59/590</td><td>1.36 (0.99, 1.86)</td><td>Not applicable</td><td>0.06</td></tr><tr><td>All-cause mortality (28 days)&#x02013;sepsis<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib20" ref-type="bibr">20</xref></td><td>204/662</td><td>374/1172</td><td>0.94 (0.74, 1.19)</td><td>37% (0.21)</td><td>0.60</td></tr><tr><td>renal replacement therapy<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib20" ref-type="bibr">20</xref><hr/></td><td>45/3473<hr/></td><td>41/3460<hr/></td><td>1.09 (0.72, 1.67)<hr/></td><td>Not applicable<hr/></td><td>0.68<hr/></td></tr><tr><td/><td colspan="2">Length of stay<hr/></td><td>MD (95% <italic>CI</italic>)</td><td>Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</td><td>Test for effect (<italic>p</italic> value)</td></tr><tr><td><hr/></td><td>albumin<hr/></td><td>NS<hr/></td><td><hr/></td><td><hr/></td><td><hr/></td></tr><tr><td>Finfer S<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref></td><td>6.5&#x000a0;&#x000b1;&#x000a0;6.6</td><td>6.2&#x000a0;&#x000b1;&#x000a0;6.2</td><td>0.30 (&#x02212;0.00, 0.60)</td><td>Not applicable</td><td>0.05</td></tr></tbody></table><table-wrap-foot><fn><p>AKI: acute kidney injury; <italic>CI</italic>: confidence interval; HES: hydroxyethyl starch; MD: mean difference; NS: normal saline; RIFLE: risk, injury, failure, loss, end-stage kidney disease; <italic>RR</italic>: relative risk.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec6"><title>NS vs buffered crystalloid solution</title><p id="p0045">Buffered crystalloid solution with electrolyte composition closely mimics human plasma in its content of electrolytes, osmolality, and pH.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref> And it has been considered as a good alternative to NS for critically ill patients with AKI.<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref> However, from two RCTs<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref> results (<xref rid="tbl5" ref-type="table">Table&#x000a0;5</xref>), we concluded that when compared with NS, the buffered crystalloid solution cannot reduce mortality or the risk of AKI. One cluster randomized trials<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> indicated that there was no significant different between NS and Ringer's lactate solution. Another cost-minimization analysis<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> results suggested that the use of Plasma-Lyte A was associated with a relatively higher fluid acquisition cost but a reduced need for magnesium replacement in critically injured trauma patients. Therefore, further large scale RCTs are needed to assess the efficacy in higher-risk populations and significant adverse events.<table-wrap id="tbl5" position="float"><label>Table&#x000a0;5</label><caption><p>Comparison of buffered crystalloid and NS on fluid resuscitation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">No. of patients<hr/></th><th rowspan="2"><italic>RR</italic> (95% <italic>CI</italic>)</th><th rowspan="2">Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</th><th rowspan="2">Test for effect (<italic>p</italic> value)</th></tr><tr><th>Buffered crystalloid</th><th>NS</th></tr></thead><tbody><tr><td>All-cause mortality (90 days)<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></td><td>87/1152</td><td>95/1110</td><td>1.05 (0.78, 1.40)</td><td>Not applicable</td><td>0.75</td></tr><tr><td>All-cause mortality (28 days)<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></td><td>3/22</td><td>4/24</td><td>1.50 (0.40, 5.65)</td><td>Not applicable</td><td>0.55</td></tr><tr><td>AKI- RIFLE- risk<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></td><td>123/1067</td><td>107/1025</td><td>1.10 (0.86, 1.41)</td><td>Not applicable</td><td>0.43</td></tr><tr><td>AKI- RIFLE- injury<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></td><td>46/1067</td><td>57/1025</td><td>0.78 (0.53, 1.13)</td><td>Not applicable</td><td>0.19</td></tr><tr><td>AKI- RIFLE- failure<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></td><td>54/1067</td><td>36/1025</td><td>1.44 (0.95, 2.18)</td><td>Not applicable</td><td>0.08</td></tr><tr><td>renal replacement therapy<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref><hr/></td><td>38/1152<hr/></td><td>38/1110<hr/></td><td>0.96 (0.62, 1.50)<hr/></td><td>Not applicable<hr/></td><td>0.87<hr/></td></tr><tr><td/><td colspan="2">No. of patients<hr/></td><td>MD (95% <italic>CI</italic>)</td><td>Heterogeneity I<sup>2</sup> (<italic>p</italic> value)</td><td>Test for effect (<italic>p</italic> value)</td></tr><tr><td><hr/></td><td>Buffered crystalloid<hr/></td><td>NS<hr/></td><td><hr/></td><td><hr/></td><td><hr/></td></tr><tr><td>Received pRBC transfusion<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></td><td>22</td><td>24</td><td>&#x02212;5.00 (&#x02212;38.99, 28.99)</td><td>Not applicable</td><td>0.77</td></tr></tbody></table><table-wrap-foot><fn><p>AKI: acute kidney injury; <italic>CI</italic>: confidence interval; MD: mean difference; NS: normal saline; pRBC: packed red blood cells; RIFLE: risk, injury, failure, loss, end-stage kidney disease; <italic>RR</italic>: relative risk.</p></fn></table-wrap-foot></table-wrap></p><p id="p0050">In this review, we compared NS vs other fluids for IV fluid therapy in critically ill patients. There is little doubt that excess exogenous chloride administration has been shown to induce renal artery vasoconstriction, AKI, hyperchloremic metabolic acidosis, gastrointestinal dysfunction, and the secretion of inflammatory cytokines.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib33" ref-type="bibr">33</xref> Although some observational studies have reported an increased mortality risk associated with the use of NS,<xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref> our results and some recent meta-analysis<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib36" ref-type="bibr">36</xref>, <xref rid="bib37" ref-type="bibr">37</xref> results showed that patients mortality and the risk of AKI were not changed with the excess exogenous chloride administration.</p><p id="p0055">Unfortunately, inappropriate NS infusion management in hospitals may lead to clinical relative adverse events, prolong length of stay in ICU or increase the mortality. Many of the errors in NS infusion management are due to inadequate knowledge and training. Several survey research<xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref> also suggested that lack of adequate clinician preparation, poor fluid balance monitoring and inadequate knowledge are associated with increased clinical risk and harm. Meanwhile, improved knowledge led to improved confidence in NS infusion management.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Therefore, it is necessary to use the present evidence to manage NS infusion, and we summarized some principles as follows.<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0060">Assess the fluid and electrolyte status of critically ill patients. Provide NS for patients whose demand cannot be met through oral or enteral routes, and stop as soon as possible.</p></list-item><list-item id="o0015"><label>2.</label><p id="p0065">A NS infusion management plan should be made, in which NS prescription over the next 24&#x000a0;h and monitoring program were indispensable.</p></list-item><list-item id="o0020"><label>3.</label><p id="p0070">The rate and volume of NS should be carefully considered; and the 4&#x000a0;Rs<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> (resuscitation, routine maintenance, redistribution and reassessment) should be also remembered (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>).<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>The 4 Rs-resuscitation, routine maintenance, replacement and redistribution.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref></p></caption><graphic xlink:href="gr1"/></fig></p></list-item><list-item id="o0025"><label>4.</label><p id="p0075">Other sources of fluid and electrolyte intake should be taken into account, including any oral or enteral intake, and intake from drugs, IV nutrition, blood and blood products.</p></list-item><list-item id="o0030"><label>5.</label><p id="p0080">If possible, provide written information for patients and their family members.</p></list-item></list></p><p id="p0085">In conclusion, NS as the most commonly used IV fluid for critically ill patients occupies a very important position in fluid resuscitation. A good understanding of its advantage and disadvantage when compared with other fluid prescribed for critically ill patients is conducive to make good clinical decision.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Myburgh</surname><given-names>J.A.</given-names></name><name><surname>Mythen</surname><given-names>M.G.</given-names></name></person-group><article-title>Resuscitation fluids</article-title><source>N&#x000a0;Engl J Med</source><volume>369</volume><year>2013</year><fpage>1243</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">24066745</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Scales</surname><given-names>K.</given-names></name><name><surname>NICE</surname><given-names>C.G.</given-names></name></person-group><article-title>174: intravenous fluid therapy in adults in hospital</article-title><source>Br J Nurs</source><volume>23</volume><year>2014</year><fpage>S6</fpage><lpage>S8</lpage><pub-id pub-id-type="pmid">24763276</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>L.</given-names></name><name><surname>Calzavacca</surname><given-names>P.</given-names></name><name><surname>Bailey</surname><given-names>M.</given-names></name></person-group><article-title>Systemic and renal haemodynamic effects of&#x000a0;fluid bolus therapy: sodium chloride versus sodium octanoate-balanced solution</article-title><source>Crit Care Resusc</source><volume>16</volume><year>2014</year><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">24588433</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>A.H.</given-names></name><name><surname>Cox</surname><given-names>E.F.</given-names></name><name><surname>Francis</surname><given-names>S.T.</given-names></name></person-group><article-title>A&#x000a0;randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte(R) 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers</article-title><source>Ann Surg</source><volume>256</volume><year>2012</year><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">22580944</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Yunos</surname><given-names>N.M.</given-names></name><name><surname>Bellomo</surname><given-names>R.</given-names></name><name><surname>Story</surname><given-names>D.</given-names></name></person-group><article-title>Bench-to-bedside review: chloride in critical illness</article-title><source>Crit Care</source><volume>14</volume><year>2010</year><fpage>226</fpage><pub-id pub-id-type="pmid">20663180</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Young</surname><given-names>P.</given-names></name></person-group><article-title>Saline is the solution for crystalloid resuscitation</article-title><source>Crit Care Med</source><volume>44</volume><year>2016</year><fpage>1538</fpage><lpage>1540</lpage><pub-id pub-id-type="pmid">27153047</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Morsing</surname><given-names>P.</given-names></name><name><surname>Velazquez</surname><given-names>H.</given-names></name><name><surname>Ellison</surname><given-names>D.</given-names></name></person-group><article-title>Resetting of tubuloglomerular feedback by interrupting early distal flow</article-title><source>Acta Physiol Scand</source><volume>148</volume><year>1993</year><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">8333296</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Semler</surname><given-names>M.W.</given-names></name><name><surname>Rice</surname><given-names>T.W.</given-names></name></person-group><article-title>Saline is not the first choice for crystalloid resuscitation fluids</article-title><source>Crit Care Med</source><volume>44</volume><year>2016</year><fpage>1541</fpage><lpage>1544</lpage><pub-id pub-id-type="pmid">27428117</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>C.</given-names></name><name><surname>Thompson</surname><given-names>K.</given-names></name><name><surname>Finfer</surname><given-names>S.</given-names></name></person-group><article-title>Hydroxyethyl starch versus saline for resuscitation of patients in intensive care: long-term outcomes and cost-effectiveness analysis of a cohort from CHEST</article-title><source>Lancet Respir Med.</source><volume>4</volume><year>2016</year><fpage>818</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">27324967</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Rackow</surname><given-names>E.C.</given-names></name><name><surname>Falk</surname><given-names>J.L.</given-names></name><name><surname>Fein</surname><given-names>I.A.</given-names></name></person-group><article-title>Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock</article-title><source>Crit Care Med</source><volume>11</volume><year>1983</year><fpage>839</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">6194934</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>van der Heijden</surname><given-names>M.</given-names></name><name><surname>Verheij</surname><given-names>J.</given-names></name><name><surname>van Nieuw Amerongen</surname><given-names>G.P.</given-names></name></person-group><article-title>Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia</article-title><source>Crit Care Med</source><volume>37</volume><year>2009</year><fpage>1275</fpage><lpage>1281</lpage><pub-id pub-id-type="pmid">19242338</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Dubin</surname><given-names>A.</given-names></name><name><surname>Pozo</surname><given-names>M.O.</given-names></name><name><surname>Casabella</surname><given-names>C.A.</given-names></name></person-group><article-title>Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients</article-title><source>J&#x000a0;Crit Care</source><volume>25</volume><year>2010</year><fpage>659.e1</fpage><lpage>659.e8</lpage></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Guidet</surname><given-names>B.</given-names></name><name><surname>Martinet</surname><given-names>O.</given-names></name><name><surname>Boulain</surname><given-names>T.</given-names></name></person-group><article-title>Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study</article-title><source>Crit Care</source><volume>16</volume><year>2012</year><fpage>R94</fpage><pub-id pub-id-type="pmid">22624531</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Myburgh</surname><given-names>J.A.</given-names></name><name><surname>Finfer</surname><given-names>S.</given-names></name><name><surname>Bellomo</surname><given-names>R.</given-names></name></person-group><article-title>Hydroxyethyl starch or saline for fluid resuscitation in intensive care</article-title><source>N&#x000a0;Engl J Med</source><volume>367</volume><year>2012</year><fpage>1901</fpage><lpage>1911</lpage><pub-id pub-id-type="pmid">23075127</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Annane</surname><given-names>D.</given-names></name><name><surname>Siami</surname><given-names>S.</given-names></name><name><surname>Jaber</surname><given-names>S.</given-names></name></person-group><article-title>Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial</article-title><source>JAMA</source><volume>310</volume><year>2013</year><fpage>1809</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">24108515</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Han</surname><given-names>X.D.</given-names></name></person-group><article-title>[The effect of different fluids on early fluid resuscitation in septic shock]</article-title><source>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue</source><volume>20</volume><year>2008</year><fpage>472</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">18687174</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>James</surname><given-names>M.F.</given-names></name><name><surname>Michell</surname><given-names>W.L.</given-names></name><name><surname>Joubert</surname><given-names>I.A.</given-names></name></person-group><article-title>Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma)</article-title><source>Br J Anaesth</source><volume>107</volume><year>2011</year><fpage>693</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">21857015</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Veneman</surname><given-names>T.F.</given-names></name><name><surname>Oude Nijhuis</surname><given-names>J.</given-names></name><name><surname>Woittiez</surname><given-names>A.J.</given-names></name></person-group><article-title>Human albumin and starch administration in critically ill patients: a prospective randomized clinical trial</article-title><source>Wien Klin Wochenschr</source><volume>116</volume><year>2004</year><fpage>305</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">15237655</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>L.A.</given-names></name><name><surname>Fergusson</surname><given-names>D.</given-names></name><name><surname>Cook</surname><given-names>D.J.</given-names></name></person-group><article-title>Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial</article-title><source>Can J Anaesth</source><volume>55</volume><year>2008</year><fpage>819</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">19050085</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Finfer</surname><given-names>S.</given-names></name><name><surname>Bellomo</surname><given-names>R.</given-names></name><name><surname>Boyce</surname><given-names>N.</given-names></name></person-group><article-title>A&#x000a0;comparison of albumin and saline for fluid resuscitation in the intensive care unit</article-title><source>N&#x000a0;Engl J Med</source><volume>350</volume><year>2004</year><fpage>2247</fpage><lpage>2256</lpage><pub-id pub-id-type="pmid">15163774</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e114666</object-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Laffan</surname><given-names>M.A.</given-names></name><name><surname>Waheed</surname><given-names>U.</given-names></name></person-group><article-title>Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality</article-title><source>BMJ</source><volume>349</volume><year>2014</year><fpage>g4561</fpage><pub-id pub-id-type="pmid">25099709</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Latour-Perez</surname><given-names>J.</given-names></name></person-group><article-title>New recommendations for the use of serum albumin in patients with severe sepsis and septic shock</article-title><source>Crit Care Med</source><volume>41</volume><year>2013</year><fpage>e289</fpage></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Lyu</surname><given-names>P.F.</given-names></name><name><surname>Murphy</surname><given-names>D.J.</given-names></name></person-group><article-title>Economics of fluid therapy in critically ill patients</article-title><source>Curr Opin Crit Care</source><volume>20</volume><year>2014</year><fpage>402</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">24979711</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Yunos</surname><given-names>N.M.</given-names></name><name><surname>Bellomo</surname><given-names>R.</given-names></name><name><surname>Glassford</surname><given-names>N.</given-names></name></person-group><article-title>Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis</article-title><source>Intensive Care Med</source><volume>41</volume><year>2015</year><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">25518951</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Pfortmueller</surname><given-names>C.A.</given-names></name><name><surname>Fleischmann</surname><given-names>E.</given-names></name></person-group><article-title>Acetate-buffered crystalloid fluids: current knowledge, a systematic review</article-title><source>J&#x000a0;Crit Care</source><volume>35</volume><year>2016</year><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">27481742</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Yunos</surname><given-names>N.M.</given-names></name><name><surname>Bellomo</surname><given-names>R.</given-names></name><name><surname>Hegarty</surname><given-names>C.</given-names></name></person-group><article-title>Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults</article-title><source>JAMA.</source><volume>308</volume><year>2012</year><fpage>1566</fpage><lpage>1572</lpage><pub-id pub-id-type="pmid">23073953</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Krajewski</surname><given-names>M.L.</given-names></name><name><surname>Raghunathan</surname><given-names>K.</given-names></name><name><surname>Paluszkiewicz</surname><given-names>S.M.</given-names></name></person-group><article-title>Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation</article-title><source>Br J Surg</source><volume>102</volume><year>2015</year><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">25357011</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J.B.</given-names></name><name><surname>Utter</surname><given-names>G.H.</given-names></name><name><surname>Schermer</surname><given-names>C.R.</given-names></name></person-group><article-title>Saline versus Plasma-Lyte A in initial resuscitation of trauma patients: a randomized trial</article-title><source>Ann Surg</source><volume>259</volume><year>2014</year><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">23732264</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Young</surname><given-names>P.</given-names></name><name><surname>Bailey</surname><given-names>M.</given-names></name><name><surname>Beasley</surname><given-names>R.</given-names></name></person-group><article-title>Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the split randomized clinical trial</article-title><source>JAMA</source><volume>314</volume><year>2015</year><fpage>1701</fpage><lpage>1710</lpage><pub-id pub-id-type="pmid">26444692</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Semler</surname><given-names>M.W.</given-names></name><name><surname>Wanderer</surname><given-names>J.P.</given-names></name><name><surname>Ehrenfeld</surname><given-names>J.M.</given-names></name></person-group><article-title>Balanced crystalloids versus saline in the intensive care unit: the SALT randomized trial</article-title><source>Am J Respir Crit Care Med</source><volume>195</volume><year>2017</year><fpage>1362</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">27749094</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.A.</given-names></name><name><surname>Duby</surname><given-names>J.J.</given-names></name><name><surname>Utter</surname><given-names>G.H.</given-names></name></person-group><article-title>Cost-minimization analysis of two fluid products for resuscitation of critically injured trauma patients</article-title><source>Am J Health Syst Pharm</source><volume>71</volume><year>2014</year><fpage>470</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">24589538</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Frazee</surname><given-names>E.</given-names></name><name><surname>Kashani</surname><given-names>K.</given-names></name></person-group><article-title>Fluid management for critically ill patients: a review of the current state of fluid therapy in the intensive care unit</article-title><source>Kidney Dis (Basel).</source><volume>2</volume><year>2016</year><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">27536694</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Raghunathan</surname><given-names>K.</given-names></name><name><surname>Shaw</surname><given-names>A.</given-names></name><name><surname>Nathanson</surname><given-names>B.</given-names></name></person-group><article-title>Association between the choice&#x000a0;of&#x000a0;IV crystalloid and in-hospital mortality among critically ill adults with&#x000a0;sepsis*</article-title><source>Crit Care Med</source><volume>42</volume><year>2014</year><fpage>1585</fpage><lpage>1591</lpage><pub-id pub-id-type="pmid">24674927</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Raghunathan</surname><given-names>K.</given-names></name><name><surname>Bonavia</surname><given-names>A.</given-names></name><name><surname>Nathanson</surname><given-names>B.H.</given-names></name></person-group><article-title>Association between initial fluid choice and subsequent in-hospital mortality during the resuscitation of adults with septic shock</article-title><source>Anesthesiology</source><volume>123</volume><year>2015</year><fpage>1385</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">26414499</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Rochwerg</surname><given-names>B.</given-names></name><name><surname>Alhazzani</surname><given-names>W.</given-names></name><name><surname>Sindi</surname><given-names>A.</given-names></name></person-group><article-title>Fluid resuscitation in sepsis: a systematic review and network meta-analysis</article-title><source>Ann Intern Med</source><volume>161</volume><year>2014</year><fpage>347</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">25047428</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>S.H.</given-names></name><name><surname>Rizvi</surname><given-names>S.I.</given-names></name><name><surname>Patel</surname><given-names>N.N.</given-names></name></person-group><article-title>Meta-analysis of colloids versus crystalloids in critically ill, trauma and surgical patients</article-title><source>Br J Surg</source><volume>103</volume><year>2016</year><fpage>14</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">26522616</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>L.H.</given-names></name><name><surname>Chong</surname><given-names>S.</given-names></name><name><surname>French</surname><given-names>P.</given-names></name></person-group><article-title>The efficiency of fluid balance charting: an evidence-based management project</article-title><source>J&#x000a0;Nurs Manag</source><volume>10</volume><year>2002</year><fpage>103</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">11882111</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Coombes</surname><given-names>I.D.</given-names></name><name><surname>Mitchell</surname><given-names>C.A.</given-names></name><name><surname>Stowasser</surname><given-names>D.A.</given-names></name></person-group><article-title>Safe medication practice: attitudes of medical students about to begin their intern year</article-title><source>Med Educ.</source><volume>42</volume><year>2008</year><fpage>427</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">18338996</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>C.</given-names></name><name><surname>Noonan</surname><given-names>C.L.</given-names></name><name><surname>Monagle</surname><given-names>J.P.</given-names></name></person-group><article-title>Preparedness for internship: a survey of new interns in a large Victorian health service</article-title><source>Aust Health Rev</source><volume>35</volume><year>2011</year><fpage>146</fpage><lpage>1451</lpage><pub-id pub-id-type="pmid">21612725</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Weisgerber</surname><given-names>M.</given-names></name><name><surname>Flores</surname><given-names>G.</given-names></name><name><surname>Pomeranz</surname><given-names>A.</given-names></name></person-group><article-title>Student competence in fluid and electrolyte management: the impact of various teaching methods</article-title><source>Ambul Pediatr</source><volume>7</volume><year>2007</year><fpage>220</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">17512882</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>A.F.</given-names></name></person-group><article-title>Outpatient management of electrolyte imbalances associated with anorexia nervosa and bulimia nervosa</article-title><source>J&#x000a0;Infusion Nurs</source><volume>28</volume><year>2005</year><fpage>118</fpage><lpage>122</lpage></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="book" id="sref43"><person-group person-group-type="author"><name><surname>National Clinical guideline Centre (UK)</surname></name></person-group><chapter-title>Intravenous Fluid Therapy: Intravenous Fluid Therapy in Adults in Hospital</chapter-title><year>2013</year><publisher-name>Royal College of Physucuans (UK)</publisher-name><publisher-loc>London</publisher-loc><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/25340240" id="intref0015">https://www.ncbi.nlm.nih.gov/pubmed/25340240</ext-link></element-citation></ref></ref-list><fn-group><fn id="d31e983"><p id="ntpara0010">Peer review under responsibility of Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.</p></fn></fn-group></back></article>